Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Equity Ratio (2017 - 2025)

Inmune Bio (INMB) has disclosed Equity Ratio for 9 consecutive years, with 0.73 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 10.37% to 0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.73 through Dec 2025, down 10.37% year-over-year, with the annual reading at 0.73 for FY2025, 10.37% down from the prior year.
  • Equity Ratio hit 0.73 in Q4 2025 for Inmune Bio, down from 0.76 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.96 in Q1 2021 to a low of 0.6 in Q1 2024.
  • Historically, Equity Ratio has averaged 0.75 across 5 years, with a median of 0.75 in 2022.
  • Biggest five-year swings in Equity Ratio: decreased 24.3% in 2021 and later skyrocketed 30.25% in 2025.
  • Year by year, Equity Ratio stood at 0.8 in 2021, then decreased by 8.46% to 0.73 in 2022, then dropped by 10.85% to 0.66 in 2023, then rose by 23.85% to 0.81 in 2024, then dropped by 10.37% to 0.73 in 2025.
  • Business Quant data shows Equity Ratio for INMB at 0.73 in Q4 2025, 0.76 in Q3 2025, and 0.77 in Q2 2025.